Opdivo's New cHL Approvals Reframe Bristol-Myers Squibb Growth Story [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Opdivo has received new approvals in the United States and European Union for use in classical Hodgkin Lymphoma across adult and pediatric patients. The expanded indications cover newly diagnosed and relapsed or refractory patients, including specific pediatric and young adult groups with limited treatment options. These regulatory decisions broaden Bristol-Myers Squibb's oncology portfolio and extend Opdivo's reach in hematology-oncology. Bristol-Myers Squibb (NYSE: BMY) is trading at around $57.48, with a return of 7.5% year to date and 9.6% over five years. Recent short-term returns show a 2.7% decline over the past week and a 5.2% decline over the past month, while the 1-year and 3-year returns, at 1.1% and 2.6% declines, reflect a mixed recent share price profile. For investors tracking NYSE: BMY, the broadened Opdivo label in the U.S. and EU adds a fresh, product-based development
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb [Yahoo! Finance]Yahoo! Finance
- Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Why Bristol-Myers Squibb (BMY) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb (BMY) had its "hold (c)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 3/27/26 - Form 15-12G
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form ARS
- BMY's page on the SEC website